LXEH vs UTI

Head-to-Head Stock Analysis & Investment Rating

Last Updated: Oct 01, 2026

LXEH

47.7
AI Score
VS
LXEH Wins

UTI

46.2
AI Score

Investment Advisor Scores

LXEH

48score
Recommendation
HOLD

UTI

46score
Recommendation
HOLD

AI Analyst Insights

AI insights temporarily unavailable

Detailed Metrics Comparison

Metric LXEH UTI Winner
Revenue 4.41M 835.62M UTI
Net Income -17.43M 63.02M UTI
Net Margin -395.4% 7.5% UTI
Operating Income -5.20M 83.47M UTI
ROE -79.6% 19.2% UTI
ROA -38.5% 7.6% UTI
Total Assets 45.32M 826.14M UTI
Cash 1.83M 127.36M UTI
Current Ratio 0.28 1.07 UTI
Free Cash Flow -44.96M 55.35M UTI

Relative Price Performance (Last 90 Days)

LXEH 1M: +1.4% · 3M: +10.6% UTI 1M: -7.4% · 3M: -61.2%

Current Technical Phase

LXEH

Neutral
Hold

Mixed signals - no dominant trend phase, RSI 48

RSI (14): 47.5 · Price: $1.57

UTI

Markdown
Sell / avoid

Price below a falling SMA50 (slope -26.9%), weak momentum, RSI 35

RSI (14): 34.9 · Price: $19.38

Fundamentals Snapshot

Metric LXEH UTI
Market Cap — —
Forward P/E 0.0 26.4
Trailing P/E — 30.7
Revenue (TTM) — —
Revenue Growth 0.0% 0.1%
Gross Margin -0.1% 0.6%
Operating Margin -0.7% 0.0%
EPS -8.90 0.62
Dividend Yield — —

Frequently Asked Questions

Based on our detailed analysis, LXEH is currently the stronger investment candidate based on our comprehensive scoring model.

We analyze revenue and earnings growth rates in the "Growth" section above. Generally, the company with higher year-over-year revenue and EPS growth is fostering better expansion. Check the table above for the specific growth percentages.

Valuation is determined by metrics like the P/E Ratio and PEG Ratio. A lower P/E typically suggests a stock is cheaper relative to its earnings. Refer to the "Valuation" section in our comparison table to see which stock currently trades at a more attractive multiple.